551 reports of this reaction
3.4% of all ENCORAFENIB reports
#7 most reported adverse reaction
NEOPLASM PROGRESSION is the #7 most commonly reported adverse reaction for ENCORAFENIB, manufactured by Array BioPharma Inc.. There are 551 FDA adverse event reports linking ENCORAFENIB to NEOPLASM PROGRESSION. This represents approximately 3.4% of all 16,241 adverse event reports for this drug.
Patients taking ENCORAFENIB who experience neoplasm progression should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
NEOPLASM PROGRESSION is moderately reported among ENCORAFENIB users, representing a notable but not dominant share of adverse events.
In addition to neoplasm progression, the following adverse reactions have been reported for ENCORAFENIB:
The following drugs have also been linked to neoplasm progression in FDA adverse event reports:
NEOPLASM PROGRESSION has been reported as an adverse event in 551 FDA reports for ENCORAFENIB. This does not prove causation, but indicates an association observed in post-market surveillance data.
NEOPLASM PROGRESSION accounts for approximately 3.4% of all adverse event reports for ENCORAFENIB, making it a notable side effect.
If you experience neoplasm progression while taking ENCORAFENIB, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.